Business Context and Reporting Period
Company: CorMedix Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2010
Business Stage: Development-stage pharmaceutical company focused on cardiorenal disease.
Key Event: Completed an Initial Public Offering (IPO) in March 2010, converting all outstanding convertible debt and related party notes into equity.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2010 | Six Months Ended June 30, 2009 | Balance Sheet (June 30, 2010) |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss | $(8,010,021) | $(2,344,728) | N/A |
| Operating Expenses | $4,921,969 | $1,270,800 | N/A |
| Interest Expense | $3,093,763 | $1,076,011 | N/A |
| Cash and Cash Equivalents | N/A | N/A | $10,585,717 |
| Total Assets | N/A | N/A | $10,990,758 |
| Total Liabilities | N/A | N/A | $1,171,175 |
| Stockholders' Equity | N/A | N/A | $9,819,583 |
| Net Cash Used in Operating Activities | $(1,369,933) | $(1,186,659) | N/A |
| Net Cash Provided by Financing Activities | $10,457,270 | $0 | N/A |
Material Changes vs. Prior Period
- Debt Elimination: As of June 30, 2010, the company had zero outstanding senior convertible notes, related party notes, or Galenica notes. All debt was converted to equity during the March 2010 IPO. This contrasts with December 31, 2009, when total current liabilities included approximately $16.9 million in debt and accrued interest.
- Liquidity Surge: Cash and cash equivalents increased from $1.5 million at year-end 2009 to $10.6 million at June 30, 2010, driven by net IPO proceeds of approximately $10.5 million.
- Expense Increase: Operating expenses for the six months ended June 30, 2010, rose significantly to $4.9 million from $1.3 million in the prior year. This increase was primarily due to a non-cash charge of $2.6 million for stock issued to licensors (anti-dilution provision) and increased stock-based compensation related to the IPO.
- Interest Expense: Interest expense for the six-month period increased to $3.1 million (from $1.1 million) due to non-cash charges associated with the conversion of debt, including a $1.1 million beneficial conversion feature charge and write-offs of debt discounts and deferred financing fees.
Outlook, Risks, and Management Commentary
- Capital Runway: Management believes current cash resources ($10.6 million) are sufficient to fund operations through the end of the first quarter of 2012.
- Product Pipeline:
- CRMD003: A liquid for preventing central venous catheter infections. The company intends to submit an Investigational Device Exemption (IDE) by the end of 2010 to begin a pivotal trial in 2011.
- CRMD001: An oral formulation of deferiprone for contrast-induced nephropathy (CIN). Patient dosing for a Phase II "proof of concept" study began in June 2010.
- Risks: The company has no revenue and expects to continue incurring substantial losses. Future profitability depends on clinical success, regulatory approval, and commercialization. Additional financing will likely be required before 2012 to complete development.
- Internal Controls: Material weaknesses in financial reporting identified in Q1 2010 (lack of segregation of duties) were remediated by Q2 2010 through new policies and the hiring of an outside accounting firm for independent review.
Investor Verification Checklist
- Capital Adequacy: Verify the burn rate against the stated runway to Q1 2012, considering the high cost of upcoming Phase II/III trials.
- Non-Cash Expenses: Confirm the impact of the $2.6 million stock issuance to licensors and $1.1 million beneficial conversion feature charge on the reported net loss, as these do not represent cash outflows.
- Dilution: Review the total share count (11.4 million outstanding) and the significant number of warrants and options (approx. 6.4 million potentially dilutive securities) issued during the IPO and debt conversions.
- Clinical Milestones: Monitor the submission of the IDE for CRMD003 and the results of the CRMD001 Phase II study initiated in June 2010.
- Related Party Transactions: Note the history of debt conversions involving related parties (Paramount BioSciences) and the termination of the consulting agreement with Paramount Corporate Development, LLC.